Managed Account Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Managed Account Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$297K	Sell	36,837 -9,081	-20%	-$66.7K	﹤0.01%	2403
2015 Q1	$303K	Buy	45,918 +14,624	+47%	+$99.9K	﹤0.01%	2346
2014 Q4	$199K	Buy	31,294 +19,789	+172%	+$160K	﹤0.01%	2331
2014 Q3	$114K	Buy	11,505 +4,859	+73%	+$51.9K	﹤0.01%	2363
2014 Q2	$75K	Buy	6,646 +1,424	+27%	+$15.3K	﹤0.01%	2365
2014 Q1	$63K	Buy	5,222 +2,147	+70%	+$27.4K	﹤0.01%	2349
2013 Q4	$39K	Buy	3,075 +2,013	+190%	+$32K	﹤0.01%	2383
2013 Q3	$18K	Buy	1,062 +379	+55%	+$6.36K	﹤0.01%	2400
2013 Q2	$10K	Buy	+683	New	+$10.4K	﹤0.01%	2432

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

MCM

Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return

TRSOTSOK

Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return

Managed Account Advisors's LXRX Position: Q2 2015 in Review

Managed Account Advisors reduced its Lexicon Pharmaceuticals (LXRX) stake by 20% in Q2 2015, selling an estimated $66.7K and leaving 36,837 shares worth $297K. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

Managed Account Advisors first reported a position in LXRX in Q2 2013 and has held it in 9 quarters since. The position peaked at $303K in Q1 2015. 94 funds tracked by Wall St. Rank hold LXRX as of Q2 2015.

Managed Account Advisors held 36,837 shares of Lexicon Pharmaceuticals worth $297K as of Q2 2015.
Managed Account Advisors sold 9,081 Lexicon Pharmaceuticals shares in Q2 2015, an estimated $66.7K.
Lexicon Pharmaceuticals made up ﹤0.01% of Managed Account Advisors's portfolio in Q2 2015, its #2403 holding.
Managed Account Advisors first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 9 quarters since.
Managed Account Advisors's Lexicon Pharmaceuticals position peaked at $303K in Q1 2015.
94 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2015.

Based on Managed Account Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.